查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
到 2028 年的 3D 生物打印市場預測 - 按組件、材料、應用、最終用戶和地區進行的全球分析
市場調查報告書
商品編碼
1273606

到 2028 年的 3D 生物打印市場預測 - 按組件、材料、應用、最終用戶和地區進行的全球分析

3D Bioprinting Market Forecasts to 2028 - Global Analysis By Component, Material, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3個工作天內

價格

根據Stratistics MRC，2022年全球3D生物打印市場規模將達到20.5億美元，預計2028年將達到55億美元，預測期內增長17.9%。預計以 100% 的複合年增長率增長。

在稱為 3D 生物打印的過程中，活細胞與生物材料相結合，以實現細胞和生物墨水的精確逐層沉積。 它的特點是在 3D 環境中保持細胞活力的分層結構特性，並且可以創建多方面和復雜的組織。 這項技術的最終結果可能是自然模仿構成人體的組織和結構的生物學和功能特性的產品。

根據Interesting Engineering的一篇文章，悉尼新南威爾士大學的工程師們成功開發出一種3D生物打印設備“F3DB”，可以直接將多層生物材料轉移到組織和內臟表面。據說已經公佈了。

市場動態

驅動程序

擴大 3D 生物打印在製藥和化妝品行業的應用

製藥和化妝品行業越來越多地使用 3D 生物打印技術，對市場產生了巨大影響。 3D 生物打印允許創建傳統技術無法實現的複雜 3D 結構。 這使得複雜的藥物配方和分子、人造皮膚和毛囊等化妝品的生產成為可能。 製藥和化妝品行業對 3D 生物打印產品的需求不斷增長，這是市場的主要驅動力。

約束

缺乏合格的專業人員

主要的市場製約因素之一是市場上缺乏合格的專業人員。 隨著對尖端 3D 生物打印技術的需求不斷增長，合格人員的短缺阻礙了市場的擴張。 3D生物打印設備的操作和維護需要熟練的專業人員。 合格專業人員的短缺削弱了 3D 生物打印技術發揮其全部潛力的潛力。 僱用和培訓合格人員的高成本也是抑制市場擴張的一個因素。

機會

政府財政支持

世界各國政府正在合作資助涉及 3D 生物打印的研發項目。 例如，五所研究型大學最初從美國食品和藥物管理局 (FDA) 獲得了總額為 25 億美元的撥款，用於 3D 生物打印的研發。 資助方包括哈佛大學、卡內基梅隆大學、羅格斯大學、麻省理工學院和佐治亞理工學院。 這是預測期內推動 3D 生物打印市場收入增長的關鍵因素。

威脅

缺乏監管標準

3D 生物打印監管標準的缺乏預計會阻礙市場收入的增長。 例如，負責監督生物製品營銷的 FDA 生物製品評估與研究中心 (CBER) 既未批准 3D 打印生物製品，也未就其使用提出明確建議。 然而，監管標準的缺乏制約了生物3D打印市場的發展。

COVID-19 的影響：

由於供應鏈中斷、對治療藥物和材料的需求增加以及製造技術的進步，COVID-19 大流行顯著加速了這些領域的技術發展。 隨著受 COVID-19 影響的人數增加，對器官和組織生產的需求也在增加。 許多 3D 生物打印市場參與者正在開發 COVID-19 疫苗，以減輕該流行病的影響。 對藥品的需求正在增長，行業參與者的數量也在增長。 此外，3D 打印社區支持開發必要的醫院設備以應對 COVID-19 的情況。

預計 3D 生物打印機細分市場將成為預測期內最大的細分市場

由於藥片廣泛用於治療各種慢性病，預計 3D 生物打印機部分在預測期內將佔據最大的市場份額。 對藥品的需求不斷增長以及生物製藥在該技術中的有效應用是推動該領域發展的其他因素。 隨著行業參與者數量的增加，對藥品的需求也在增加。 全世界有數百萬人出於醫療原因定期服用藥片和膠囊。 因此，該細分市場有望在預測期內實現盈利增長。

預計醫療行業在預測期內的複合年增長率最高。

醫療行業有望在預測期內實現良好增長。 由於藥片廣泛用於治療各種慢性疾病，3D 生物打印市場正在增長。 此外，對藥品不斷增長的需求以及該技術對生物製藥的有效利用也推動了這一領域的發展。

市場份額最高的地區

在預測期內，預計北美將主導全球市場。 北美目標人口數量的增加是該地區佔據主導地位的原因。 由於該地區存在主要參與者和先進的醫療保健基礎設施，預計北美 3D 生物打印市場將有增長機會。 預計區域參與者增加對各種研發計劃的投資也將推動未來幾年的市場增長。

複合年增長率最高的地區：

亞太地區預計在預測期內的複合年增長率最高，原因是其老年人口眾多以及政府為加強醫療保健行業而採取的強有力舉措和政策。 日本政府預測，再生醫學產業到2030年將增長到1萬億日元的規模。 由於 COVID-19 案件數量的增加和政府研發支出的增加，日本和中國占了大部分收入。 此外，COVID-19死亡率上升和器官捐獻者短缺預計將推動區域市場的擴張。

主要發展：

2022 年 6 月，Humabiologics 和 REGEMAT 3D 將滿足歐洲藥物檢測和生物打印市場不斷增長的需求，並為更廣泛的生命科學客戶群提供服務，包括學術機構及其行業合作夥伴已宣布一項非獨家經銷協議。

2022 年 5 月，Organovo Holdings 宣布成功開發出第一個以克羅恩病的發現和驗證為目標的炎症性腸病 (IBD) 模型。 根據內部數據，該公司認為其 IBD 模型可以重新定義克羅恩病患者與未患克羅恩病患者不同的重要生物學方面。

2021 年 4 月，Aspect Biosystems, Inc. 宣布與糖尿病研究和宣傳領域的先驅 JDRF 建立合作夥伴關係。 通過此次合作，兩家公司將專注於開發可治療 1 型糖尿病的 3D 生物打印組織。

我們的報告提供了什麼

  • 區域和國家/地區細分市場份額評估
  • 向新進入者提出戰略建議
  • 2020、2021、2022、2025 和 2028 年的綜合市場數據
  • 市場驅動因素（市場趨勢、制約因素、機遇、威脅、挑戰、投資機會、建議）。
  • 根據市場預測在關鍵業務領域提出戰略建議
  • 競爭格局映射關鍵共同趨勢。
  • 公司簡介，包括詳細的戰略、財務狀況和近期發展
  • 映射最新技術進步的供應鏈趨勢

免費定制優惠：

購買此報告的客戶將獲得以下免費定制選項之一：

  • 公司簡介
    • 其他市場參與者的綜合概況（最多 3 家公司）
    • 主要參與者的 SWOT 分析（最多 3 家公司）
  • 區域細分
    • 根據客戶的要求對主要國家/地區的市場估計/預測/複合年增長率（注意：基於可行性檢查）。
  • 競爭基準
    • 根據產品組合、區域影響力和戰略聯盟對主要參與者進行基準測試

內容

第 1 章執行摘要

第二章前言

  • 概覽
  • 利益相關者
  • 調查範圍
  • 調查方法
    • 數據挖掘
    • 數據分析
    • 數據驗證
    • 研究方法
  • 調查來源
    • 主要研究來源
    • 二級研究來源
    • 假設

第三章市場趨勢分析

  • 司機
  • 約束因素
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第 4 章波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第 5 章全球 3D 生物打印市場：按組件分類

  • 3D 生物打印機
    • 微擠壓生物打印
    • 噴墨 3D 生物打印
    • 注射器/擠壓生物打印
    • 激光輔助生物打印
    • 基於立體光刻的生物打印
    • 磁性 3D 生物打印
    • 其他 3D 生物打印機
  • 生物墨水
    • 自然
    • 混合型
    • 綜合

第 6 章全球 3D 生物打印市場：按材料分類

  • 生物材料
    • 活細胞
    • 水凝膠
    • 細胞外基質
    • 其他生物材料

第 7 章全球 3D 生物打印市場：按應用

  • 醫學
    • 組織和器官的產生
    • 藥丸
    • 假肢和植入物
    • 其他藥物
  • 藥物測試和調查
  • 臨床移植
  • 食品檢驗
  • 再生醫學
  • 消費者/個人產品測試
  • 癌症研究
  • 生物傳感器
  • 其他用途

第 8 章全球 3D 生物打印市場：按最終用戶分類

  • 研究和學術機構
  • 生物製藥公司
  • 醫院

第 9 章全球 3D 生物打印市場：按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 意大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 新西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中東和非洲
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 卡塔爾
    • 南非
    • 其他中東和非洲地區

第10章主要發展

  • 合同、夥伴關係、協作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章公司簡介

  • 3D Bioprinting Solutions
  • 3D Systems Corporation
  • Advanced Solutions Life Sciences, LLC
  • Allevi Inc.
  • Arcam AB
  • Aspect Biosystems Ltd.
  • Bico group ab
  • Bio3D Technologies Pte. Ltd.
  • Cellink
  • Collplant Biotechnologies Ltd.
  • Cyfuse Biomedical K.K.
  • Electro Optical Systems
  • Envision TEC GmbH
  • Foldink Life Science Technologies
  • Formlabs, Inc.
  • GE Healthcare
  • GeSIM GmbH
  • Inventia Life Science PTY LTD
  • Optomec Inc.
  • Organovo Holdings Inc.
  • Pandorum Technologies pvt. ltd.
  • Poietis
  • Precise Bio
  • REGEMAT 3D
  • Regenovo Biotechnology Co. Ltd.
  • Renishaw plc.
  • Revotek co., ltd.
  • Rokit Healthcare, inc.
  • Stratasys Ltd
Product Code: SMRC22904

According to Stratistics MRC, the Global 3D Bioprinting Market is accounted for $2.05 billion in 2022 and is expected to reach $5.50 billion by 2028 growing at a CAGR of 17.9% during the forecast period. Live cells are combined with biomaterials in a process called 3D bioprinting that enables precise layer-by-layer deposition of the cells or bio-ink. This is distinguished by hierarchical structural characteristics that preserve cellular viability in 3D environments to produce multifaceted and complex tissues. The end results of this technique can be products that mimic the biological and functional characteristics of the tissues and structures that make up the human body naturally.

According to an article by Interesting Engineering, engineers at the University of New South Wales, Sydney, published a paper wherein they successfully developed a 3D bio-printed device, F3DB, that can directly transfer multi-layered biomaterials on the surface of the tissues and internal organs.

Market Dynamics:

Driver:

Increasing use of 3D bioprinting in the pharmaceutical and cosmetic industries

The market has been significantly influenced by the growing use of 3D bioprinting in the pharmaceutical and cosmetic industries. Complex 3D structures can be created using 3D bioprinting, which is not possible with conventional techniques. This has made it possible to produce intricate drug formulations and molecules, as well as cosmetic products like synthetic skin, hair follicles, and other tissues. The pharmaceutical and cosmetic industries' rising need for 3D bioprinted products has been a key market driver.

Restraint:

Lack of qualified professionals

One of the main market constraints is the lack of qualified professionals in the market. The market's expansion has been hampered by a lack of qualified professionals as demand for cutting-edge 3D bioprinting technology rises. To operate and maintain 3D bioprinting equipment, skilled professionals are required. The likelihood that 3D bioprinting technology will realize its full potential has been reduced by a lack of qualified professionals. The high cost of hiring and training qualified professionals is another factor impeding market expansion.

Opportunity:

Funding from the governments

Governments from various nations are working together to fund research and development projects involving 3D bioprinting. For instance, the first five research universities received a grant from the US Food and Drug Administration (FDA) for three dimensional bioprinting research and development totaling USD 2.5 billion. The grant recipients included Harvard University, Carnegie Mellon University, Rutgers University, Massachusetts Institute of Technology, and Georgia Institute of Technology. This is a significant factor that is predicted to boost the three-dimensional bioprinting market's revenue growth over the forecast period.

Threat:

Absence of regulatory standards

The absence of regulatory standards for 3D bioprinting is anticipated to impede market revenue growth. For instance, the FDA's Center for Biologics Evaluation and Research (CBER), which oversees the sale of biological commodities, has neither approved any 3D-printed biological products nor made any explicit recommendations regarding their use. The absence of regulatory standards, however, places a constraint on the growth of the 3D bioprinting market.

COVID-19 Impact:

Due to disrupted supply chains, increased demand for treatments and materials, and manufacturing technology advancements, the COVID-19 pandemic significantly accelerated these fields' technological development. There is a growing need for organ and tissue production as the number of COVID-19 illness cases rises. The COVID-19 vaccine is being developed by a number of 3D bioprinting market participants to mitigate the effects of the outbreak. As well as the number of industry participants, the demand for pharmaceutical products is rising. Moreover, the 3D printing community responded to the COVID-19 situation by supporting the development of essential hospital equipment.

The 3D bioprinters segment is expected to be the largest during the forecast period

Due to the widespread use of pharmaceutical pills to treat a variety of chronic conditions, the 3D bioprinters segment is expected to hold the largest market share during the forecast period. The growing demand for pharmaceuticals and the effective application of bio-drugs in this technology are other factors driving the segment. Along with an increase in industry participants, the demand for pharmaceutical products is also rising. Millions of people regularly take pills and capsules for medical reasons all over the world. As a result, it is anticipated that this market segment will expand profitably over the course of the forecast period.

The medical segment is expected to have the highest CAGR during the forecast period

The medical segment is expected to witness lucrative growth during the forecast period. The market for 3D bioprinting is expanding due to the widespread use of pharmaceutical pills to treat a variety of chronic diseases. Additionally, the segment is also being driven by the expanding demand for medicines and the efficient use of bio-drugs in this technology.

Region with largest share:

Over the forecast period, North America is anticipated to dominate the global market. The increased target population count in North America is blamed for the area's dominance. The North American 3D bioprinting market is expected to experience growth opportunities due to the presence of key players and the region's sophisticated healthcare infrastructure. In the upcoming years, it is anticipated that increased regional players' investments in a variety of R&D initiatives will also help the market grow.

Region with highest CAGR:

Asia Pacific is estimated to witness the highest CAGR over the projection timeframe, owing to a senior population and favorable government initiatives and policies to strengthen the healthcare sector in this region. By 2030, the Japanese government projects that the regenerative medicine industry will have grown to 1 trillion yen. Due to the rise in COVID-19 cases and government R&D spending, Japan and China accounted for the lion's share of the revenue. Furthermore, COVID-19's increased mortality rate and the scarcity of organ donors are expected to fuel the expansion of the regional market.

Key players in the market:

Some of the key players profiled in the 3D Bioprinting Market include: 3D Bioprinting Solutions, 3D Systems Corporation, Advanced Solutions Life Sciences, LLC, Allevi Inc., Arcam AB, Aspect Biosystems Ltd., Bico group ab, Bio3D Technologies Pte. Ltd., Cellink, Collplant Biotechnologies Ltd., Cyfuse Biomedical K.K., Electro Optical Systems, Envision TEC GmbH, Foldink Life Science Technologies, Formlabs, Inc., GE Healthcare, GeSIM GmbH, Inventia Life Science PTY LTD, Optomec Inc., Organovo Holdings Inc., Pandorum Technologies pvt. ltd., Poietis, Precise Bio, REGEMAT 3D, Regenovo Biotechnology Co. Ltd., Renishaw plc., Revotek co., ltd., Rokit Healthcare, inc. and Stratasys Ltd.

Key Developments:

In June 2022, Humabiologics and REGEMAT 3D announced a non-exclusive distribution agreement in order to respond to the increasing demand and serve a broader life science customer base of academic institutes and its industry partners in the European drug testing and bioprinting market.

In May 2022, Organovo Holdings announced it had successfully advanced its first Inflammatory Bowel Disease (IBD) model to target the discovery and validation of Crohn's Disease. Based on the internal data, the company believes its IBD model can correctly demonstrate important aspects of Crohn's patient biology that differ from a non-diseased person.

In April 2021, Aspect Biosystems Ltd announced a partnership with JDRF, a pioneer in diabetes research and advocacy. Through the partnership, the companies will focus on developing 3D bio-printed tissue that is capable of treating type 1 diabetes.

Components Covered:

  • 3D Bioprinters
  • Bioinks

Materials Covered:

  • Biomaterials

Applications Covered:

  • Medical
  • Drug Testing & Research
  • Clinical Transplantation
  • Food Testing
  • Regenerative Medicine
  • Consumer/Personal Product Testing
  • Cancer Research
  • Biosensors
  • Other Applications

End Users Covered:

  • Research Organizations & Academic Institutes
  • Biopharmaceutical Companies
  • Hospitals

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global 3D Bioprinting Market, By Component

  • 5.1 Introduction
  • 5.2 3D Bioprinters
    • 5.2.1 Microextrusion Bioprinting
    • 5.2.2 Inkjet 3D Bioprinting
    • 5.2.3 Syringe/extrusion Bioprinting
    • 5.2.4 Laser-Assisted Bioprinting
    • 5.2.5 Stereolithography-Based Bioprinting
    • 5.2.6 Magnetic 3D bioprinting
    • 5.2.7 Other 3D Bioprinters
  • 5.3 Bioinks
    • 5.3.1 Natural
    • 5.3.2 Hybrid
    • 5.3.3 Synthetic

6 Global 3D Bioprinting Market, By Material

  • 6.1 Introduction
  • 6.2 Biomaterials
    • 6.2.1 Living Cells
    • 6.2.2 Hydrogels
    • 6.2.3 Extracellular Matrices
    • 6.2.4 Other Biomaterials

7 Global 3D Bioprinting Market, By Application

  • 7.1 Introduction
  • 7.2 Medical
    • 7.2.1 Tissue And Organ Generation
    • 7.2.2 Medical Pills
    • 7.2.3 Prosthetics And Implants
    • 7.2.4 Other Medicals
  • 7.3 Drug Testing & Research
  • 7.4 Clinical Transplantation
  • 7.5 Food Testing
  • 7.6 Regenerative Medicine
  • 7.7 Consumer/Personal Product Testing
  • 7.8 Cancer Research
  • 7.9 Biosensors
  • 7.10 Other Applications

8 Global 3D Bioprinting Market, By End User

  • 8.1 Introduction
  • 8.2 Research Organizations & Academic Institutes
  • 8.3 Biopharmaceutical Companies
  • 8.4 Hospitals

9 Global 3D Bioprinting Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 3D Bioprinting Solutions
  • 11.2 3D Systems Corporation
  • 11.3 Advanced Solutions Life Sciences, LLC
  • 11.4 Allevi Inc.
  • 11.5 Arcam AB
  • 11.6 Aspect Biosystems Ltd.
  • 11.7 Bico group ab
  • 11.8 Bio3D Technologies Pte. Ltd.
  • 11.9 Cellink
  • 11.10 Collplant Biotechnologies Ltd.
  • 11.11 Cyfuse Biomedical K.K.
  • 11.12 Electro Optical Systems
  • 11.13 Envision TEC GmbH
  • 11.14 Foldink Life Science Technologies
  • 11.15 Formlabs, Inc.
  • 11.16 GE Healthcare
  • 11.17 GeSIM GmbH
  • 11.18 Inventia Life Science PTY LTD
  • 11.19 Optomec Inc.
  • 11.20 Organovo Holdings Inc.
  • 11.21 Pandorum Technologies pvt. ltd.
  • 11.22 Poietis
  • 11.23 Precise Bio
  • 11.24 REGEMAT 3D
  • 11.25 Regenovo Biotechnology Co. Ltd.
  • 11.26 Renishaw plc.
  • 11.27 Revotek co., ltd.
  • 11.28 Rokit Healthcare, inc.
  • 11.29 Stratasys Ltd

List of Tables

  • Table 1 Global 3D Bioprinting Market Outlook, By Region (2020-2028) ($MN)
  • Table 2 Global 3D Bioprinting Market Outlook, By Component (2020-2028) ($MN)
  • Table 3 Global 3D Bioprinting Market Outlook, By 3D Bioprinters (2020-2028) ($MN)
  • Table 4 Global 3D Bioprinting Market Outlook, By Microextrusion Bioprinting (2020-2028) ($MN)
  • Table 5 Global 3D Bioprinting Market Outlook, By Inkjet 3D Bioprinting (2020-2028) ($MN)
  • Table 6 Global 3D Bioprinting Market Outlook, By Syringe/extrusion Bioprinting (2020-2028) ($MN)
  • Table 7 Global 3D Bioprinting Market Outlook, By Laser-Assisted Bioprinting (2020-2028) ($MN)
  • Table 8 Global 3D Bioprinting Market Outlook, By Stereolithography-Based Bioprinting (2020-2028) ($MN)
  • Table 9 Global 3D Bioprinting Market Outlook, By Magnetic 3D bioprinting (2020-2028) ($MN)
  • Table 10 Global 3D Bioprinting Market Outlook, By Other 3D Bioprinters (2020-2028) ($MN)
  • Table 11 Global 3D Bioprinting Market Outlook, By Bioinks (2020-2028) ($MN)
  • Table 12 Global 3D Bioprinting Market Outlook, By Natural (2020-2028) ($MN)
  • Table 13 Global 3D Bioprinting Market Outlook, By Hybrid (2020-2028) ($MN)
  • Table 14 Global 3D Bioprinting Market Outlook, By Synthetic (2020-2028) ($MN)
  • Table 15 Global 3D Bioprinting Market Outlook, By Material (2020-2028) ($MN)
  • Table 16 Global 3D Bioprinting Market Outlook, By Biomaterials (2020-2028) ($MN)
  • Table 17 Global 3D Bioprinting Market Outlook, By Living Cells (2020-2028) ($MN)
  • Table 18 Global 3D Bioprinting Market Outlook, By Hydrogels (2020-2028) ($MN)
  • Table 19 Global 3D Bioprinting Market Outlook, By Extracellular Matrices (2020-2028) ($MN)
  • Table 20 Global 3D Bioprinting Market Outlook, By Other Biomaterials (2020-2028) ($MN)
  • Table 21 Global 3D Bioprinting Market Outlook, By Application (2020-2028) ($MN)
  • Table 22 Global 3D Bioprinting Market Outlook, By Medical (2020-2028) ($MN)
  • Table 23 Global 3D Bioprinting Market Outlook, By Tissue And Organ Generation (2020-2028) ($MN)
  • Table 24 Global 3D Bioprinting Market Outlook, By Medical Pills (2020-2028) ($MN)
  • Table 25 Global 3D Bioprinting Market Outlook, By Prosthetics And Implants (2020-2028) ($MN)
  • Table 26 Global 3D Bioprinting Market Outlook, By Other Medicals (2020-2028) ($MN)
  • Table 27 Global 3D Bioprinting Market Outlook, By Drug Testing & Research (2020-2028) ($MN)
  • Table 28 Global 3D Bioprinting Market Outlook, By Clinical Transplantation (2020-2028) ($MN)
  • Table 29 Global 3D Bioprinting Market Outlook, By Food Testing (2020-2028) ($MN)
  • Table 30 Global 3D Bioprinting Market Outlook, By Regenerative Medicine (2020-2028) ($MN)
  • Table 31 Global 3D Bioprinting Market Outlook, By Consumer/Personal Product Testing (2020-2028) ($MN)
  • Table 32 Global 3D Bioprinting Market Outlook, By Cancer Research (2020-2028) ($MN)
  • Table 33 Global 3D Bioprinting Market Outlook, By Biosensors (2020-2028) ($MN)
  • Table 34 Global 3D Bioprinting Market Outlook, By Other Applications (2020-2028) ($MN)
  • Table 35 Global 3D Bioprinting Market Outlook, By End User (2020-2028) ($MN)
  • Table 36 Global 3D Bioprinting Market Outlook, By Research Organizations & Academic Institutes (2020-2028) ($MN)
  • Table 37 Global 3D Bioprinting Market Outlook, By Biopharmaceutical Companies (2020-2028) ($MN)
  • Table 38 Global 3D Bioprinting Market Outlook, By Hospitals (2020-2028) ($MN)

Note: Tables for North America, Europe, Asia Pacific, South America and Middle East & Africa Regions are also represented in the same manner as above.